Add like
Add dislike
Add to saved papers

Successful Management of an "Unresectable" Intrahepatic Cholangiocarcinoma with Neoadjuvant Systemic Therapy, Chemoembolization, and Extended Hepatectomy with Portal Vein Reconstruction.

Curēus 2018 May 29
Cholangiocarcinoma is a rare, but invariably fatal primary hepatic tumor that is often diagnosed at advanced stages with minimal options of surgical cure. Relatively few patients diagnosed with cholangiocarcinoma are considered surgical candidates, owing to the extent of the disease at presentation, the presence of vascular invasion or extrahepatic disease, and/or poor functional status with advanced age being most commonly associated. There is no clear consensus for the management of advanced cholangiocarcinomas, as the current literature is typically based on limited patient numbers and anecdotal experiences at best. This case report represents the successful management of a large, advanced intrahepatic cholangiocarcinoma using multiple treatment modalities including systemic chemotherapy, liver-directed therapy, portal vein embolization, and extended hepatectomy with portal vein resection and reconstruction.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app